COLL - Collegium Pharmaceutical, Inc.
| Previous Close | 13.89 |
| Open | 14.02 |
| Bid | 12.75 x 800 |
| Ask | 14.90 x 1000 |
| Day's Range | 13.98 - 15.15 |
| 52 Week Range | 13.10 - 29.90 |
| Volume | 511,961 |
| Avg. Volume | 427,678 |
| Market Cap | 491.731M |
| Beta (3Y Monthly) | 0.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.00 |
| Earnings Date | Feb 27, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.17 |
- Zacks•2 days ago
ASRT or COLL: Which Is the Better Value Stock Right Now?
ASRT vs. COLL: Which Stock Is the Better Value Option?
- GlobeNewswire•4 days ago
Collegium to Host Conference Call to Discuss Fourth Quarter 2018 Financial Results and Provide Corporate Update
STOUGHTON, Mass., Feb. 13, 2019 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on.
- Simply Wall St.•4 days ago
Breakeven On The Horizon For Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL): Collegium Pharmaceutical, Inc.,Read More...
- Zacks•18 days ago
ASRT vs. COLL: Which Stock Should Value Investors Buy Now?
ASRT vs. COLL: Which Stock Is the Better Value Option?
- GlobeNewswire•last month
Report: Developing Opportunities within Enterprise Products Partners, Antero Midstream Partners LP, Integrated Device Technology, Collegium Pharmaceutical, GAIN Capital, and United Technologies — Future Expectations, Projections Moving into 2019
NEW YORK, Jan. 17, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•last month
Collegium Provides Full-Year 2019 Financial Guidance
Collegium Pharmaceutical, Inc. (COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management today provided full-year 2019 guidance for Xtampza ER revenues, Nucynta Franchise revenues, and total operating expenses. “With strong growth for Xtampza ER in 2018 and the addition of the Nucynta Franchise, Collegium built a solid foundation upon which to progress in the year ahead,” said Joe Ciaffoni, Chief Executive Officer. Xtampza ER revenue for 2019 is estimated to be between $95 million and $105 million.
- Insider Monkey•2 months ago
Do Hedge Funds Love Collegium Pharmaceutical Inc (COLL)?
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors endured a torrid quarter, which certainly propelled them to adjust their equity holdings so as to maintain the desired risk profile. As […]
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of COLL earnings conference call or presentation 8-Nov-18 9:30pm GMT
Q3 2018 Collegium Pharmaceutical Inc Earnings Call
- Simply Wall St.•2 months ago
How Financially Strong Is Collegium Pharmaceutical, Inc. (NASDAQ:COLL)?
While small-cap stocks, such as Collegium Pharmaceutical, Inc. (NASDAQ:COLL) with its market cap of US$634m, are popular for their explosive growth, investors should also be aware of their balance sheet Read More...
- Insider Monkey•3 months ago
Collegium Pharmaceutical, Inc. (NASDAQ:COLL): Are Hedge Funds Right About This Stock?
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]
- Zacks•3 months ago
Collegium Pharmaceutical (COLL) Reports Q3 Loss, Lags Revenue Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -127.27% and -6.94%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Collegium Pharmaceutical: 3Q Earnings Snapshot
The Canton, Massachusetts-based company said it had a loss of 50 cents per share. Losses, adjusted for non-recurring costs and stock option expense, came to 25 cents per share. The results did not meet ...
- Benzinga•3 months ago
Collegium Pharmaceutical Q3 Earnings Preview
Don't be caught off-guard: Collegium Pharmaceutical, Inc. - Common Stock (NASDAQ: COLL ) releases its next round of earnings this Thursday, Nov. 8. View more earnings on COLL Want to skip the homework ...
- Zacks•4 months ago
Collegium Pharmaceutical (COLL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Market Realist•6 months agoWhat Collegium Pharmaceutical’s Valuation Trend Indicates
Collegium Pharmaceutical’s net loss decreased from $21.12 million in the second quarter of 2017 to $13.06 million in the second quarter of 2018, which translated into a net loss per share of $0.40 in the second quarter as compared with a net loss per share of $0.72 in the second quarter of 2017. In August 2018, of the total eight analysts covering Collegium Pharmaceutical, three analysts have given the stock a “strong buy” rating, and five analysts have given Collegium Pharmaceutical a “buy” rating. The mean rating for Collegium Pharmaceutical stock is 1.63 with a target price of $31.67.
Market Realist•6 months agoSurge in Xtampza Sales Bodes Well for Collegium Pharmaceutical
Collegium Pharmaceutical (COLL) is a specialty pharmaceutical company focused on bringing to market products for people suffering from pain. In January 2018, Collegium began commercializing Nucynta products. Collegium Pharmaceutical generated total revenues of $73.06 million in the second quarter of 2018 as compared with $3.56 million in the second quarter of 2017.
Market Realist•6 months agoHow Is Insys Therapeutics Positioned in H2 2018?
The US government is taking steps to address the opioid epidemic and rapidly rising addiction levels in the country. On August 16, President Trump asked the Attorney General to start filing federal lawsuits against certain companies that supply opioids to hospitals. In this series, we’ll analyze the financial performance, products, analysts’ views, valuation metrics, and the stock performance of Insys Therapeutics (INSY), Cara Therapeutics (CARA), Collegium Pharmaceutical (COLL), and Pacira Pharmaceuticals (PCRX).
